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Abstract 44 
We systematically identified and analysed published and unpublished data comparing HPV 45 
prevalence in prevaccination and postvaccination time periods, to consider changes in 46 
nonvaccine HPV types after vaccine introduction. Nine studies provided HPV prevalence 47 
data from 13,886 females aged ≤19 years (younger females) and 23,340 females aged 20-24 48 
years (older females). Following vaccine introduction, there was some evidence of cross-49 
protection for HPV31 among younger females (prevalence ratio (PR) (95%CI)=0.73(0.58-50 
0.91)) but little evidence of a reduction in HPV33 and HPV45. There was evidence of a slight 51 
increase in two nonvaccine high-risk HPV types: HPV39 and HPV52 (younger females: 52 
PR=1.27(1.05-1.54) and 1.34(1.13-1.59) respectively), and in two possible high-risk types 53 
HPV53 and HPV73 (younger females: PR=1.51(1.10-2.06) and PR=1.36(1.03-1.80)). Given 54 
the inconsistency in findings between age groups and the vaccine used, and possible 55 
alternative explanations for the increases, there was no clear evidence for type-replacement. 56 
Continued monitoring of these HPV types is important. 57 
 58 
Article Summary Line: Following introduction of HPV vaccination, there were some 59 
changes in the prevalence of non-vaccine HPV types, but there was no clear evidence for 60 
type-replacement 61 
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Introduction  62 
Persistent infection with a high-risk human papillomavirus (HPV) genotype is a necessary 63 
cause of cervical cancer.(1) Two high-risk types (HPV16 and HPV18) cause approximately 64 
70-80% of cervical cancers.(2-4) The HPV vaccines which are currently commercially 65 
available have been shown in trial settings to have close to 100% vaccine efficacy against 66 
cervical disease caused by vaccine-specific high-risk HPV types: HPV16 and 18 for the 67 
bivalent and quadrivalent vaccines; HPV31, 33, 45, 52, and 58 for the new nonavalent 68 
vaccine.(5-7) Clinical trial data for the bivalent and quadrivalent vaccines have also shown 69 
low to moderate protection against some of the other high-risk HPV types which are 70 
phylogenetically related to HPV16 and HPV18 (i.e. cross-protection).(8;9) 71 
HPV vaccination programmes have now been introduced in many countries.(10) A recently 72 
published systematic review and meta-analysis assessed the population impact of HPV 73 
vaccination on the vaccine HPV types, showing strong evidence that HPV vaccination is 74 
highly effective against infection with these types.(11) The review also looked at closely 75 
related HPV types, but only as a single group, demonstrating some evidence of cross-76 
protection overall in a population setting.(11) However, assessment of changes in the 77 
prevalence of closely related HPV types combined may not provide full evidence of the 78 
impact of vaccination, as it could potentially conceal decreases or increases in the prevalence 79 
of individual types. Grouping HPV types together limited the possibility to look at cross-80 
protection with specific HPV types and/or changes in other individual nonvaccine types. For 81 
example, one theoretical concern is that the reductions in the prevalence of HPV16 and 82 
HPV18 infection could lead to other high-risk HPV types occupying that niche and becoming 83 
a more common cause of disease. Whilst this was not observed in the clinical trials,(12) it is 84 
important to monitor this potential for type replacement in population settings following the 85 
introduction of national HPV vaccination. Furthermore, since other HPV types are often far 86 
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less common than the vaccine HPV types, within an individual study there is limited scope to 87 
determine whether type replacement has occurred; combining data from several reports 88 
improves the power to investigate this. 89 
Thus, the aim of this study was to investigate the population level impact of HPV vaccination 90 
programmes, using the bivalent or quadrivalent vaccines, on the type-specific prevalence of 91 
infection of individual nonvaccine high-risk HPV types.  92 
 93 
Methods 94 
Objectives 95 
We compared data on HPV prevalence from surveys conducted prior to the introduction of an 96 
HPV vaccination programme with surveys after their introduction in similar populations in 97 
the same country, to determine the change in HPV prevalence for each nonvaccine high-risk 98 
HPV type (at the time of this search, any eligible study would have considered changes 99 
following vaccination using the bivalent or quadrivalent vaccines, hence high-risk HPV types 100 
included in the nonavalent vaccine only were considered nonvaccine HPV types). Each 101 
individual type was presented separately. We included HPV types for which some cross-102 
protection had been demonstrated in clinical trials (HPV31, HPV33, phylogenetically related 103 
to HPV16 and HPV45 phylogenetically related to HPV18),(8;9;13) other high-risk HPV 104 
types included in the nonavalent vaccine (HPV52 and HPV58), other high-risk and probable 105 
high-risk HPV types (HPV35, HPV39, HPV51, HPV56, HPV59, and HPV68), and other 106 
possibly high-risk HPV types (HPV26, HPV53, HPV70, HPV73, and HPV82) as defined by 107 
the International Agency for Research on Cancer.(14) 108 
This systematic review and meta-analysis was reported in accordance with PRISMA 109 
guidelines.(15)  110 
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 111 
Search strategy and selection criteria 112 
Embase, Medline, LILACS and African Index Medicus were searched for eligible 113 
publications from 2007 (the date the first HPV vaccination programmes were introduced ) up 114 
to 19th February 2016. The search strategy incorporated MeSH terms and relevant free text 115 
words in the title/abstract to identify relevant studies which included mention of both 116 
vaccination and HPV infection or a related disease (including, but not limited to, HPV-related 117 
pre-cancerous lesions and cancers and genital warts; see Supplementary Material for full 118 
search terms). There were no language restrictions.  119 
Eligible studies were those which assessed population-level impact of HPV vaccination over 120 
time by comparing the prevalence of HPV infection (defined by the detection of HPV DNA) 121 
in a prevaccination period to a postvaccination period. Studies which compared HPV-122 
infection in those vaccinated and unvaccinated as part of an individually randomised trial 123 
were excluded as they would not measure a population-level effect. Similarly, studies which 124 
only compared HPV-infection between unvaccinated and vaccinated individuals in the 125 
postvaccination period were also excluded. We also excluded studies if a very small 126 
proportion (<2%) of the postvaccination study population were vaccinated (i.e. largely 127 
unvaccinated populations). Titles and abstracts were initially reviewed for eligibility by DM. 128 
Those which were deemed to consider changes in HPV prevalence following the introduction 129 
of HPV vaccination programmes were reviewed in full. Search results were also compared to 130 
those identified in the related recent review by Drolet and colleagues which compared the 131 
pre- and postvaccination periods for the high-risk vaccine types (HPV-16/18), cross-protected 132 
types (HPV-31/33/45), and all high-risk HPV nonvaccine types combined.(11)  133 
 134 
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Data extraction and data quality 135 
Data were extracted by DM on study design, country of study and then (for both the pre- and 136 
postvaccination period) the year(s) of sample collection, study setting and population, sample 137 
size, the specimen type, the assay used for HPV-DNA testing, HPV genotypes included in the 138 
assay and demographic and sexual behaviour data collected, as well as the measure of effect 139 
for each study. Additionally, for the postvaccination period, data were extracted on the 140 
method used to ascertain estimated vaccination coverage. 141 
The potential bias from each study was assessed by considering the comparability of the 142 
study populations in the pre- vs postvaccination periods (i.e. similar setting and population 143 
demographics), the extent of adjustment for potential confounders, the suitability of the 144 
specimen type to assess HPV-DNA infection, the suitability of the assay used for accurate 145 
HPV-DNA testing (and whether this differed between the pre- and postvaccination periods) 146 
and the method used to estimate HPV vaccination coverage. External validity was assessed 147 
by considering whether the study samples were population-based. Each item was scored as 148 
either ‘low risk’ or ‘high risk’. 149 
Published data on the prevalence and prevalence ratios for individual high-risk HPV types 150 
were not always available. Authors were contacted to request the HPV type-specific 151 
prevalence in the prevaccination and postvaccination period and the prevalence ratio 152 
comparing the two periods for each of the nonvaccine high-risk HPV types. Adjusted 153 
prevalence ratio (PR; adjusted for demographics and sexual behavior data) were requested or 154 
the unadjusted PR if no data on confounders were available; unadjusted PRs were calculated 155 
if raw data were provided. For one study (Mesher et al), adjusted odds ratios were included 156 
rather than prevalence ratios in order to additionally adjust for the change in assay between 157 
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the pre- and postvaccination periods using data from a previously conducted validation 158 
study.(16) 159 
Data analysis 160 
Estimates weighted to account for selection processes were used if provided by authors (with 161 
unweighted numbers presented in Tables and Figures). Data were stratified by age-group due 162 
to expected differences in vaccination coverage and vaccine effectiveness in those vaccinated 163 
at an older age. Data were requested from authors for the same age-groups for each study 164 
(≤19 years old and 20-24 years old). Söderlund-Strand et al included data from young women 165 
aged under 13 years old hence we requested data restricted to 16-19 year olds. 166 
To allow calculation of a prevalence ratio for a prevalence of zero (in either the 167 
prevaccination or postvaccination period), a continuity correction of 0.5 was added to all 168 
cells. When the prevalence was zero for both the prevaccination and postvaccination period, 169 
the study was omitted from the meta-analysis for the relevant age-group and HPV-type. 170 
Results were further stratified by the vaccine used (i.e. bivalent or quadrivalent). Prevalence 171 
ratios within each subgroup were combined to obtain a summary prevalence ratio using a 172 
fixed effects model if data were not shown to be heterogeneous (lack of heterogeneity was 173 
determined by a p-value≥0.10 using Cochrane’s Q test and/or an I2 value<25%).(17) In 174 
sensitivity analyses, analyses were restricted to studies that used cervical, vulval or vaginal 175 
swabs as the specimen type due to the lower sensitivity to detect HPV DNA infection using 176 
urine samples.(18) 177 
 178 
Results 179 
Included studies 180 
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A total of 4,648 unique papers were identified after de-duplication of searches from all four 181 
databases (Figure 1). An initial search of title and abstracts excluded 4,508 (97.0%) papers 182 
due to ineligibility. For the remaining 140 papers, a full paper search was conducted which 183 
identified ten eligible papers. Reasons for ineligibility are shown in Figure 1. One study met 184 
all eligibility criteria but the type-specific prevalence ratios were not available from 185 
authors.(19) Therefore, a total of nine studies were included in the systematic review and 186 
meta-analysis.(16;20-27)  All eligible studies were repeat cross-sectional studies which 187 
compared changes in prevalence in populations prior to and after the introduction of a 188 
national HPV vaccination programme (Table 1). Only one study considered changes in HPV 189 
infection among males so only female populations were considered in the present analysis. 190 
Two studies were population-based national surveys (Markowitz et al (25) and Sonnenberg et 191 
al (22)), three studies were conducted among young women attending for chlamydia 192 
screening (Chow et al (26), Mesher et al (16), and Söderlund-Strand et al (27)), two studies 193 
comprised young women attending a primary care clinic, community health centre and/or a 194 
hospital-based adolescent clinics (Cummings et al (20) and Kahn et al (21)), and two studies 195 
comprised women attending for cervical screening (Cameron et al (24) and Tabrizi et al (23)) 196 
(Table 1).  197 
The assessment of methodological quality is summarised in Figure 2. The majority of studies 198 
collected some demographic and sexual behaviour data to allow appropriate adjustment of the 199 
relative risks, although the number of factors collected was limited in some studies (Cameron 200 
et al (24), Mesher et al (16), Tabrizi et al (23), and Söderlund-Strand et al (27)) (Figure 2). 201 
Details of which data were used for adjusted prevalence ratios are given in Table 1.  202 
 203 
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HPV types included in the nonavalent but not the bi- and quadrivalent HPV vaccines 204 
(HPV31, HPV33, HPV45, HPV52, and HPV58) 205 
HPV types for which there is previous evidence for cross-protection (HPV31, HPV33, and 206 
HPV45): There was evidence of a reduction in the prevalence of HPV31 (Figure 3; Table 2), 207 
for females aged ≤19 years old (PR=0.73, 95% CI: 0.58-0.91). There was little evidence of a 208 
change in prevalence for HPV33 or HPV45 in the younger age-group (PR=1.04, 95%CI: 209 
0.78-1.38 for HPV31, PR=0.96, 95%CI: 0.75-1.23 for HPV45). Results were heterogeneous 210 
for HPV31, HPV33 and HPV45 in the older age-group hence summary prevalence ratios 211 
were not calculated (Figure 3; Table 2).  212 
Other HPV types (HPV52 and HPV58): There was evidence of an increase in the prevalence 213 
of HPV52 in ≤19 year old females (PR=1.34, 95% CI: 1.13-1.59) (Figure 4; Table 2), but a 214 
summary prevalence ratio was not calculated for the older age-group due to heterogeneity. 215 
There was no evidence of a change in the prevalence of HPV58 for the younger age-group 216 
(PR=1.01, 95%CI: 0.80-1.26) although borderline evidence of an increase among those aged 217 
20-24 years (PR=1.14, 95%CI: 0.99-1.31). 218 
Other high-risk and possibly high-risk HPV types  219 
No consistent patterns across the studies were observed for the non-nonavalent vaccine HPV 220 
types (Figure S1; Table 2). There was evidence of an increased prevalence between the 221 
prevaccination period and postvaccination period in ≤19 year old females for HPV39, HPV53 222 
and HPV73 (PR=1.27, 95%CI: 1.05-1.54, PR=1.51, 95% CI: 1.10-2.06 and PR=1.36, 95% 223 
CI: 1.03-1.80 respectively). For the 20-24 year olds, there was some evidence of an increase 224 
in HPV39 (PR=1.13, 95% CI: 1.00-1.28).  225 
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Sensitivity analyses 226 
As a sensitivity analysis, we performed three additional stratified analyses (all stratified by 227 
age-group); (i) by vaccine used (i.e. bivalent or quadrivalent), (ii) by potential bias of study 228 
(relatively low potential bias, defined as fewer than three domains classified as high-risk of 229 
bias, or relatively high potential bias, defined as three or more domains classified as high-risk 230 
of bias) (Figure 2) and (iii) by vaccination coverage (low <50%, high ≥50%).  231 
For studies in settings using the bivalent vaccine, there was some evidence of an increased 232 
prevalence between the prevaccination period and postvaccination period in ≤19 year old 233 
females for HPV52, HPV53, HPV56, and HPV70 (Table S1; Figures S2, S3, and S4). The 234 
prevalence of HPV53 among 20-24 year old women also increased. For the quadrivalent 235 
vaccine, there was evidence of an increase in HPV39, HPV51, and HPV59 for females ≤19 236 
years old. Among 20-24 year olds, there was evidence of an increase in the prevalence of 237 
HPV52 and HPV70 (Table S1; Figures S2, S3, and S4). 238 
Many of the analyses stratified by potential bias of included studies gave similar results to the 239 
unstratified analyses (Table S2). However, in the younger age-group, for studies with 240 
relatively low potential bias there was no evidence of increases in HPV52 or HPV39 (which 241 
were seen when studies were unstratified). For studies with relatively high potential bias, in 242 
the younger age-group there was evidence of an increase in the prevalence of HPV51 and 243 
HPV70 which was not seen in the unstratified analysis. In the older age-group there was 244 
evidence of a decrease in HPV 33 for those studies at a relatively low potential bias (no 245 
summary estimate was provided in the unstratified analysis due to heterogeneity). For studies 246 
with a relatively high potential bias there was evidence of an increase in the prevalence of 247 
HPV52 and HPV58. There was also evidence for a decrease in the prevalence of HPV82 for 248 
both those with relatively high potential bias and relatively low potential bias (although there 249 
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was a larger decrease in those studies with relatively high potential bias; no summary 250 
estimate was provided in the unstratified analysis due to evidence for heterogeneity). 251 
Vaccination coverage was high for all studies in the younger age-group (Table S3). For older 252 
women, there was a decrease in HPV31 for studies with high vaccination coverage (no 253 
summary estimate was provided for the unstratified analysis due to heterogeneity). There was 254 
evidence of an increase in HPV39 and HPV58 (as with the unstratified analysis) although 255 
only for the studies with low coverage. There was also evidence of increases not seen in the 256 
unstratified analysis (HPV70 for low coverage studies and borderline evidence for HPV26 for 257 
high coverage studies; both types had no summary estimate for the unstratified analysis due 258 
to heterogeneity).  259 
Discussion 260 
Comprehensive postvaccination surveillance should consider not just the reductions in 261 
vaccine type-specific infection and associated diseases but also evaluate any other potential 262 
impacts of the reduction of the targeted infection. Thus, we assessed changes in the 263 
nonvaccine HPV types to determine evidence of cross protection for individual types and the 264 
potential concern that the reductions seen in certain HPV types after HPV vaccine 265 
introduction could create a niche for other, nonvaccine high-risk HPV types to become more 266 
common (i.e. type-replacement). We demonstrated evidence of a reduction in the prevalence 267 
of HPV31 in the younger age-group. In our main analysis, we show increases in other 268 
nonvaccine HPV types, HPV39, HPV52, HPV53, HPV58, and HPV73 but these increases 269 
were inconsistent between age-groups and the vaccine used.  270 
A previous systematic review evaluated changes in high-risk HPV types combined, and 271 
found some evidence of a reduction of the HPV types closely related to the vaccine types 272 
(HPV31, HPV33, and/or HPV45) when considered as a single group (PR=0.72, 95% CI: 273 
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0.54-0.96 for 13-19 year olds).(11) Our review provides evidence of a reduction in the 274 
prevalence of HPV31, but little evidence of a reduction in HPV33 or HPV45. 275 
Comparing HPV prevalence in a prevaccination period to a similar population in 276 
postvaccination period allows us to consider the population-level impact of HPV vaccination 277 
on HPV prevalence. However, these repeat cross-sectional study designs have some 278 
limitations. Although all studies included similar populations in the pre- and postvaccination 279 
periods, there may have been temporal changes in these populations over time which could 280 
affect HPV prevalence, independent of HPV vaccination. For example, there have been 281 
increases in other STI diagnoses over this same time period in some countries.(28) 282 
Furthermore, in many countries the incidence of genital warts was increasing prior to the 283 
vaccine introduction(29-31) and has continued to increase postvaccination in those not 284 
eligible for vaccination.(11) It is therefore possible that the increases in some HPV types we 285 
observed are associated with broad increases in sexual risk over time. Changes in 286 
demographics and sexual behaviour between the populations were considered when 287 
available, but it is likely that there were some unrecorded population changes and/or other 288 
temporal changes in the relative proportions of high-risk HPV types over time.(32;33) There 289 
is also more geographical variation in the relative frequency of nonvaccine HPV types in 290 
populations compared with HPV16 prevalence which, prior to vaccination programs, was the 291 
most frequent high risk type observed in almost all populations.(34)   292 
The change in assay between the pre- and postvaccination for one of the studies (Mesher et 293 
al) was a potential source of bias. A validation study comparing these two testing assays 294 
allowed odds ratios (ORs) to be adjusted for the differences in diagnostic accuracy. This 295 
adjusted odds ratio could not be converted to a prevalence ratio using the log-binomial model 296 
and thus was included as an OR.  However, given the low prevalence of individual HPV 297 
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types, the use of an OR for this study (rather than a PR) is unlikely to have affected the 298 
results substantially. 299 
Another limitation is that the broad-spectrum assays which have been used in these studies 300 
(and in baseline prevaccination evaluations globally) can lack sensitivity to detect individual 301 
HPV types when multiple types are present, particularly in the presence of another HPV type 302 
with a higher viral load. In the postvaccination period, in the absence of HPV16 and HPV18 303 
this could lead to an apparent, artificial increase in nonvaccine types (because they were 304 
underestimated in the pre-vaccine period due to the predominance of HPV16 and/or HPV18). 305 
This potential unmasking effect has been demonstrated in analytical studies;(35;36) hence 306 
some of the increases in nonvaccine types observed could be due to unmasking. 307 
Given the low prevalence of some other nonvaccine HPV types, it is a challenge to assess 308 
changes in prevalence for individual types since the introduction of HPV vaccination. By 309 
combining data from several studies, we had enhanced power to consider changes in the 310 
individual HPV types. However, even with data from 13,886 women aged ≤19 years old and 311 
23,340 women aged 20-24 years old, we still had limited power to consider changes in the 312 
very rare HPV types or to investigate the reasons for the heterogeneity in findings for some 313 
HPV types, with inconsistent evidence for increases of specific nonvaccine types between 314 
age-groups and the two vaccines. Conversely, type 1 errors can occur with multiple testing 315 
and modest evidence for increases should be interpreted with caution.   316 
We decided against performing random-effects meta-analyses in the presence of between-317 
study heterogeneity because in most instances there was inconsistency in the direction of 318 
effect, making the summary estimate (the average value of these opposing effects) 319 
uninformative(37). Exploring the causes of heterogeneity could provide some further insight 320 
into the reasons for these increases, and we carried out subgroup analyses by vaccine used, by 321 
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potential bias and by vaccine coverage. The results of the stratification by potential bias 322 
suggest that increased prevalence ratios for some HPV types may have been reported more 323 
often in the studies with relative high potential bias. However, for all three sensitivity 324 
analyses the small number of studies in each stratum limited the interpretation of these 325 
analyses. Similarly, we were limited to only eight studies for each age-group and thus at 326 
present have insufficient power to perform meta-regression analyses (as meta-regression 327 
should generally not be considered when there are fewer than ten studies)(37). As further data 328 
accrue, one useful future analysis would be to explore the association between the reductions 329 
in the HPV vaccine-types and any increases in nonvaccine HPV types (that are not due to 330 
unmasking) - if increases were due to type-replacement then we would expect to see 331 
increasing prevalence of nonvaccine HPV types as prevalence of vaccine HPV types 332 
decreases.  333 
It is encouraging that we confirm the reductions in a cross-protected HPV type. The results of 334 
this systematic review and meta-analysis do not provide any clear evidence for type-335 
replacement, as it is not clear to what extent any increases seen are due to other temporal 336 
changes, changes in the study populations, and/or an unmasking effect of broad spectrum 337 
HPV assays. Large scale epidemiological analyses using various designs have not detected 338 
evidence of any significant interactions between high-risk types; the known high evolutionary 339 
stability of these viruses, lessens the risk that type-replacement will be a problem.(38;39)  340 
The majority of women included in the surveillance studies were those vaccinated at older 341 
ages (i.e. potentially vaccinated after HPV exposure) and some studies include populations 342 
with relatively low coverage compared to nationally reported vaccination coverage for 343 
routine cohorts. Future studies should continue to monitor population prevalence of these 344 
types. In particular, populations vaccinated at a younger age with higher vaccination coverage 345 
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should be considered and, perhaps more importantly, the absolute prevalence of CIN3 lesions 346 
attributed to each high-risk HPV type.347 
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Table 1: Characteristics of studies selected for systematic review 
 
Cameron 
et al Chow et al 
Cumming
s et al Kahn et al 
Markowitz 
et al 
Mesher et 
al 
Söderlund
-Strand et 
al 
Sonnenber
g et al Tabrizi et al 
Study 
design 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Repeat 
cross-
sectional 
studies 
Country of 
study 
UK 
(Scotland) 
Australia USA USA USA 
UK 
(England) 
Sweden 
UK 
(Britain)  
Australia 
Vaccine 
introduced 
Bivalent 
Quadrival
ent 
Quadrival
ent 
Quadrival
ent 
Quadrivale
nt 
Bivalent 
Quadrival
ent 
Bivalent 
Quadrivale
nt 
Year(s) of 
sample 
collection 
Prevaccina
tion: 2009-
2010 
Postvaccin
ation: 
2011-2013 
Prevaccina
tion: 
2004-2007 
Postvaccin
ation: 
2007-2014 
Prevaccin
ation: 
1995-2005 
Postvaccin
ation: 
2010 
Prevaccin
ation: 
2006-2007 
Postvaccin
ation: 
2009-2010 
Prevaccina
tion: 2003-
2006 
Postvaccin
ation: 
2009-2012 
Prevaccin
ation: 
2008 
Postvaccin
ation: 
2010-2013 
Prevaccin
ation: 
2008 
Postvaccin
ation: 
2012-2013 
Prevaccin
ation: 
1999-2001 
Postvaccin
ation: 
2010-2012 
Prevaccinat
ion: 2005-
2007 
Postvaccina
tion: 2010-
2011 
Number of 
specimens 
tested 
Prevaccina
tion: 2705 
Postvaccin
ation: 
3010 
Prevaccina
tion: 136 
Postvaccin
ation: 328 
Prevaccin
ation: 150 
Postvaccin
ation:    75 
Prevaccin
ation: 365 
Postvaccin
ation: 383 
Prevaccina
tion: 1795 
Postvaccin
ation: 
1209 
Prevaccin
ation: 
2354 
Postvaccin
ation: 
7321 
Prevaccin
ation: 
11457 
Postvaccin
ation: 
3555 
Prevaccin
ation: 328 
Postvaccin
ation: 795 
Prevaccinat
ion: 202 
Postvaccina
tion: 1058 
Study 
population 
and setting 
Females 
(aged 20-
21 years 
old) 
attending 
for 
cervical 
screening 
as part of 
national 
cervical 
screening 
programm
e. 
Australian
-born 
females 
(aged 21 
years old 
and 
younger) 
attending 
for 
chlamydia 
screening 
at a sexual 
health 
centre in 
Melbourne 
and testing 
positive 
for 
chlamydia 
Females 
(aged 14-
17 years 
old) 
attending 
one of 
three 
primary 
care 
clinics in 
Indiana 
Females 
(aged 13-
26 years 
old) who 
had had 
sexual 
intercours
e, 
recruited 
from 
hospital 
based 
adolescent 
clinic and 
a 
communit
y health 
centre 
Females 
(aged 14-
24 years 
old) 
participati
ng in 
population 
based 
NHANES 
survey 
Sexually 
active 
females 
(aged 16-
25 year 
old) 
attending 
for 
chlamydia 
screening 
at 
communit
y sexual 
health 
settings 
Females 
(all ages) 
attending 
for 
chlamydia 
screening 
in a 
defined 
region of 
Sweden 
Sexually 
experience
d females 
(aged 18-
44 years 
old) 
selected 
via 
household
s using 
stratified 
probabilit
y sample 
survey 
(participat
ing in 
Natsal 
survey) 
Females 
(aged 18-24 
years old) 
attending 
for cervical 
screening at 
sentinel 
family 
planning 
clinics in 
Sydney, 
Melbourne 
and Perth 
Specimen 
type Residual 
LBC* 
specimen 
Cervical 
and high 
vaginal 
swab 
samples 
Self-
collected 
vaginal 
swab 
Cervicova
ginal 
swabs by 
clinician 
or self-
Self-
collected 
cervicovag
inal swab 
Residual 
vulval 
vaginal 
swab 
specimen 
Genital 
swabs 
(either 
alone or 
Urine 
sample 
Sample of 
exfoliated 
cervical 
cells 
preserved 
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collected 
swab 
immersed 
in urine) 
in 
PreservCyt 
Assay for 
HPV-DNA 
testing 
Multimetri
x HPV 
assay 
PapType 
HPV 
assay 
Linear 
Array 
HPV 
Genotypin
g test 
Linear 
Array 
HPV 
Genotypin
g test 
Linear 
Array 
HPV 
Genotypin
g test 
Prevaccin
ation: 
Linear 
Array 
HPV 
Genotypin
g test in 
those 
testing 
positive 
for Hybrid 
Capture 2 
 
Postvaccin
ation: In-
house 
multiplex 
PCR and 
Luminex 
based 
genotypin
g system 
PCR 
testing 
with 
genotypin
g by 
matrix-
assisted 
laser 
desorption 
ionization 
time-of-
flight 
(MALDI-
TOF) 
mass 
spectrome
try 
In house 
multiplex 
PCR and 
Luminex 
based 
genotypin
g system 
Amplicor 
DNA test 
for 13 high-
risk types 
(If 
negative, 
tested for 
presence of 
mucosal 
DNA using 
L1 
consensus 
primer set 
PGMY09-
PGMY11). 
If positive 
for 
Amplicor 
or 
PCMY09/P
GMY11 
PCR-
ELISA 
were 
genotyped 
using the 
Linear 
Array HPV 
genotyping 
test 
Demograp
hic and 
sexual 
behaviour 
data collected 
Scottish 
Index of 
Multiple 
Deprivatio
n, 
month/yea
r of birth 
 
These data 
were not 
used to 
adjust the 
HPV 
prevalence 
ratios in 
Age-
stratified 
prevalence 
ratios 
were 
adjusted 
for by 
number of 
male 
partners, 
100% 
condom 
use with 
all 
partners in 
Samples 
matched 
on age at 
enrolment, 
clinic site 
and 
reported 
sexual 
activity. 
Data on 
ethnicity, 
sexual 
partners in 
previous 
last year, 
Age, race, 
health care 
insurance, 
knowledg
e about 
HPV 
vaccines, 
smoking 
status, 
gynaecolo
gic history 
(number 
of 
pregnanci
es, history 
Ethnicity, 
poverty 
index and, 
for those 
reported 
ever 
having 
sex; age at 
first sex, 
lifetime 
number of 
partners, 
number of 
partners in 
the 
Age 
stratified 
prevalence 
ratios 
were 
adjusted 
for age, 
chlamydia 
positivity 
at time 
specimen 
taken and 
collection 
venue type  
All 
samples 
were 
anonymise
d 
(individua
l age was 
known) 
Extensive 
demograp
hic and 
sexual 
behaviour 
data 
collected.  
 
These data 
were not 
used to 
adjust the 
HPV 
prevalence 
ratios in 
Age, 
current use 
of 
hormonal 
contracepti
on, 
smoking 
status and 
postcode of 
residence 
 
These data 
were not 
used to 
adjust the 
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this meta-
analysis 
the past 12 
months 
status and 
anatomical 
sampling 
method 
(cervical 
vs high 
vaginal 
sample) 
sexual 
partners in 
previous 2 
months, 
lifetime 
sexual 
partners, 
instances 
of vaginal 
intercours
e in 
previous 
year and 
instances 
of vaginal 
intercours
e in the 
previous 2 
months 
 
These data 
were not 
used to 
adjust the 
HPV 
prevalence 
ratios in 
this meta-
analysis 
of STIs), 
sexual 
behaviour
s (age at 
first sex, 
number of 
male 
lifetime 
partners, 
number of 
male 
partners in 
previous 3 
months, 
anal sex, 
condom 
use) 
 
These data 
were not 
used to 
adjust the 
HPV 
prevalence 
ratios in 
this meta-
analysis 
previous 
12 months. 
 
These data 
were not 
used to 
adjust the 
HPV 
prevalence 
ratios in 
this meta-
analysis 
this meta-
analysis 
HPV 
prevalence 
ratios in 
this meta-
analysis 
Vaccinatio
n status  
Data 
linked 
from 
Scottish 
Immunisat
ion 
call/recall 
system 
and Child 
Health 
Schools 
Programm
e system 
Self-
reported. 
Data not 
available 
for all 
women 
Collected 
from 
medical 
notes 
Collected 
from 
immunisat
ion 
registry 
for 87% of 
women. 
 
Collected 
from self-
administer
ed 
questionna
ire for 
remaining 
13% of 
women. 
Self-
reported 
Not 
collected 
for 
individual
s 
Not 
collected 
for 
individual
s 
Self-
reported 
Self-
reported 
and 
validated 
against the 
National 
HPV 
vaccine 
register 
* LBC = Liquid based cytology 
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Table 2: Prevalence ratio for nonvaccine high-risk HPV types stratified by age-group 
Age-group / HPV type Number of studies 
Heterogeneity 
Prevalence ratio*  
(95% CI) I2 p-value 
≤19 year old females     
HPV types included in nonavalent vaccine     
HPV 31 8 6.4% 0.381 0.73 (0.58-0.91) 
HPV 33 8 0.0% 0.471 1.04 (0.78-1.38) 
HPV 45 8 5.5% 0.387 0.96 (0.75-1.23) 
HPV 52 8 24.0% 0.238 1.34 (1.13-1.59) 
HPV 58 8 0.0% 0.727 1.01 (0.80-1.26) 
Other high-risk HPV types     
HPV 35 8 25.1% 0.229 - 
HPV 39 8 0.0% 0.984 1.27 (1.05-1.54) 
HPV 51 8 43.6% 0.088 - 
HPV 56 8 74.3% <0.001 - 
HPV 59 8 66.8% 0.004 - 
HPV 68 8 0.0% 0.690 1.26 (0.88-1.81) 
Other possibly high-risk HPV types     
HPV 26 6 0.0% 0.478 1.63 (0.84-3.16) 
HPV 53 6 3.6% 0.394 1.51 (1.10-2.06) 
HPV 70 6 23.6% 0.257 1.34 (0.75-2.39) 
HPV 73 6 0.0% 0.961 1.36 (1.03-1.80) 
HPV 82 6 49.0% 0.081 - 
20-24 year old females     
HPV types included in nonavalent vaccine     
HPV 31 8 28.8% 0.198 - 
HPV 33 8 50.9% 0.047 - 
HPV 45 8 64.3% 0.007 - 
HPV 52 8 31.0% 0.180 - 
HPV 58 8 0.0% 0.806 1.14 (0.99-1.31) 
Other high-risk HPV types     
HPV 35 8 7.9% 0.369 1.07 (0.85-1.34) 
HPV 39 8 0.0% 0.522 1.13 (1.00-1.28) 
HPV 51 8 49.8% 0.052 - 
HPV 56 8 82.6% <0.001 - 
HPV 59 8 63.6% 0.007 - 
HPV 68 8 35.6% 0.145 - 
Other possibly high-risk HPV types     
HPV 26 6 44.3% 0.110 - 
HPV 53 6 30.8% 0.204 - 
HPV 70 6 25.1% 0.246 - 
HPV 73 6 59.2% 0.032 - 
HPV 82 6 38.3% 0.151 - 
* Summary prevalence ratio only calculated if data were not shown to be heterogeneous  
356 
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Figure Legends 
Figure 1: Flow chart for eligible studies included in systematic review 
Figure 2: Potential Bias and external validity of included studies 
Figure 3: Prevalence ratio for high-risk HPV types with evidence of cross-protection 
(HPV31, HPV33, HPV45) stratified by age-group, percentages in square brackets represent 
vaccination coverage (at least one dose) for each study/age-group 
Figure 4: Prevalence ratio for other high-risk HPV types included in the nonavalent vaccine 
(HPV52, HPV58) stratified by age-group, percentages in square brackets represent 
vaccination coverage (at least one dose) for each study/age-group 
Technical Appendix Figure 1: Prevalence ratio for other probably high-risk HPV types 
(HPV35, HPV39, HPV51, HPV56, HPV59 and HPV68) stratified by age-group, percentages 
in square brackets represent vaccination coverage (at least one dose) for each study/age-group 
Technical Appendix Figure  2: Prevalence ratio for high-risk HPV types with evidence of 
cross-protection (HPV31, HPV33, HPV45) stratified by age-group and vaccine type, 
percentages in square brackets represent vaccination coverage (at least one dose) for each 
study/age-group 
Technical Appendix Figure  3: Prevalence ratio for other high-risk HPV types included in 
the nonavalent vaccine (HPV52, HPV58)  stratified by age-group and vaccine type, 
percentages in square brackets represent vaccination coverage (at least one dose) for each 
study/age-group 
Technical Appendix Figure 4: Prevalence ratio for other probably high-risk HPV types 
(HPV35, HPV39, HPV51, HPV56, HPV59 and HPV68)  stratified by age-group and vaccine 
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type, percentages in square brackets represent vaccination coverage (at least one dose) for 
each study/age-group 
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Technical Appendix 
Search strategies  
Medline search strategy: 2410 (19 Feb 2016) 
1.   Epidemiologic Studies/ 
2.   exp case-control Studies/ 
3.   (case* and control*).tw 
4.   exp Cohort Studies/ 
5.   cohort*.tw 
6.   Cross-sectional Studies/ 
7.   (cross* and section*).tw 
8.   Seroepidemiologic Studies/ 
9.   Sentinel Surveillance/ 
10. Public Health Surveillance/ 
11. Incidence/ 
12. Prevalence/ 
13. Odds Ratio/ 
14. odds ratio.tw 
15. risk ratio.tw 
16. rate ratio.tw 
17. relative risk.tw 
18. screening method.tw 
19. effectiveness.tw 
20. observational.tw 
21. (step* and wedge*).tw 
22. Or/1-21 
23. Human Papillomavirus DNA Tests/ 
24. exp Papillomavirus Infections/ 
25. exp Papillomaviridae/ 
26. (HPV or papilloma*).tw  
27. Uterine Cervical Neoplasms/ 
28. Genital Neoplasms, Female/ 
29. Genital Diseases, Female/ 
30. Uterine Cervical Dysplasia/ 
31. (Penile ADJ1 wart).tw 
32. (cervi* or genit*).tw 
33. warts.tw 
34. condyloma*.tw 
35. neoplas*.tw 
36. dysplas*.tw 
37. lesion*.tw 
38. cancer*.tw 
39. carcin*.tw  
40. maligna*.tw  
41. disease*.tw 
42. (carcinoma adj2 situ).tw 
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43. Or/33-42  
44. And/32,43 
45. Or/23-30,44 
46. (Immunis* or immuniz* or vaccin*).tw 
47. Papillomavirus Vaccines/ 
48. Or/46-47 
49. Humans/ 
50. limit to yr=2007-2016 
51. And/22,45,48,49,50 
 
Embase search strategy: 3843 (19 Feb 2016) 
1.   Epidemiology/ 
2.   Cross-sectional study/ 
3.   (cross$ ADJ1 section$).tw 
4.   exp case control study / 
5.   (case$ ADJ1 control$).tw 
6.   cohort analysis/ 
7.   cohort$.tw 
8.   exp Disease surveillance/ 
9.   exp health survey/ 
10. incidence/ 
11. exp prevalence/ 
12. sentinel surveillance/ 
13. seroepidemiology/ 
14. risk/ 
15. infection risk/ 
16. population risk/ 
17. risk reduction/ 
18. observational study/ 
19. (odd$ ADJ1 ratio).tw 
20. (risk ADJ1 ratio).tw 
21. (rate ADJ1 ratio).tw 
22. (relative ADJ1 risk).tw 
23. (screening ADJ1 method).tw 
24. effectiveness.tw 
25. observational.tw 
26. (step$ ADJ1 wedge$).tw 
27. Or/1-26 
28. exp Papilloma virus / 
29. hpv.tw  
30. Papilloma$.tw 
31. Uterine cervix disease/ 
32. Uterine cervix dysplasia/ 
33. exp Uterine Cervix Tumor/ 
34. urogenital tract tumor/ 
35. genital tract tumor/ 
36. female genital tract tumor/ 
37. female genital tract cancer/ 
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38. gynecologic cancer/ 
39. genital tract cancer/ 
40. female genital tract cancer/ 
41. Urogenital tract cancer/ 
42. Female genital tract cancer/ 
43. female genital tumor/ 
44. female genital tract infection/ 
45. genital tract infection/ 
46. gynecologic infection/ 
47. (peni$ ADJ1 wart$).tw 
48. (cervi$ or genit$).tw 
49. wart$.tw 
50. condyloma$.tw 
51. neoplas$.tw 
52. dysplas$.tw 
53. lesion$.tw 
54. cancer$.tw 
55. carcin$.tw  
56. maligna$.tw  
57. disease$.tw 
58. (carcinoma ADJ2 situ).tw 
59. Or/49-58   
60. And/48,59 
61. Or/28-47,60 
62. (Immunis$ or immuniz$ or vaccin$).tw 
63. Wart virus vaccine/ 
64. Or/62,63  
65. Humans/  
66. limit to yr=2007-2016 
67. And/27,61,64,65,66 
 
LILACS search strategy: 58 (19 Feb 2016) 
((cross$ AND section$) OR (case$ AND control$) OR (cohort$) OR (odd$ AND ratio) OR 
(risk AND ratio) OR (rate AND ratio) OR (relative AND risk) OR effectiveness OR 
observational OR (“step wedge” OR “step-wedge” OR stepwedge)) AND (hpv OR 
Papilloma$ OR ((cervi$ or genit$) AND (wart$ OR neoplas$ OR dysplas$ OR lesion$ OR 
cancer$ OR carcin$ OR adeno$ OR squamous$ OR disease$ OR (carcinoma AND situ)))) 
AND (Immuni$ or vaccin$) AND (PD 2007 OR PD 2008 OR PD 2009 OR PD 2010 OR PD 
2011 OR PD 2012 OR PD 2013 OR PD 2014 OR PD 2015 OR PD 2016) 
 
AIM search strategy: 17 (19 Feb 2016) 
hpv OR Papilloma$ 
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Supplementary Tables 
Table S1: Prevalence ratio for non-vaccine high-risk HPV types stratified by age-group and vaccine type 
  Bivalent vaccine   Quadrivalent vaccine 
Age-group / HPV type 
Numbe
r of 
studies 
Heterogeneit
y Prevalence 
ratio*  
(95% CI) 
 Numb
er of 
studie
s 
Heterogeneity 
Prevalence 
ratio*  
(95% CI) I2 
p-
valu
e 
 I2 
p-
value 
≤19 year old females          
HPV types included in nonavalent 
vaccine 
         
HPV 31 
2 
10.4
% 
0.29
1 
0.54 (0.29-
1.03) 
 
6 
8.7
% 0.36 
0.75 (0.60-
0.96) 
HPV 33 
2 
0.0% 
0.78
5 
1.66 (0.94-
2.92) 
 
6 
0.0
% 0.687 
0.89 (0.64-
1.24) 
HPV 45 
2 
75.4
% 
0.04
4 - 
 
6 
0.0
% 0.716 
1.01 (0.76-
1.34) 
HPV 52 
2 
0.0% 
0.40
8 
1.93 (1.34-
2.77) 
 
6 
0.0
% 0.627 
1.20 (0.99-
1.47) 
HPV 58 
2 
0.0% 
0.44
5 
1.19 (0.81-
1.73) 
 
6 
0.0
% 0.742 
0.92 (0.69-
1.22) 
Other high-risk HPV types          
HPV 35 
2 
85.2
% 
0.00
9 - 
 
6 
0.0
% 0.914 
0.91 (0.58-
1.42) 
HPV 39 
2 
0.0% 
0.75
5 
1.30 (0.89-
1.91) 
 
6 
0.0
% 0.932 
1.26 (1.01-
1.58) 
HPV 51 
2 
74.9
% 
0.04
6 - 
 
6 
35.2
% 0.172 
1.16 (1.00-
1.36) 
HPV 56 
2 
18.3
% 
0.26
9 
2.08 (1.43-
3.04) 
 
6 
64.9
% 0.014 - 
HPV 59 
2 
51.9
% 
0.14
9 - 
 
6 
0.0
% 0.478 
1.27 (1.03-
1.57) 
HPV 68 
2 
0.0% 
0.44
4 
1.84 (0.62-
5.47) 
 
6 
0.0
% 0.601 
1.20 (0.82-
1.76) 
Other possibly high-risk HPV types          
HPV 26 
2 
0.0% 
0.87
3 
1.89 (0.84-
4.26) 
 
4 
26.8
% 0.251 
1.21 (0.38-
3.81) 
HPV 53 
2 
0.0% 
0.89
4 
2.22 (1.25-
3.94) 
 
4 
0.0
% 0.445 
1.28 (0.88-
1.85) 
HPV 70 
2 
0.0% 
0.95
7 
4.07 (1.43-
11.55) 
 
4 
0.0
% 0.97 
0.82 (0.41-
1.64) 
HPV 73 
2 
0.0% 
0.92
6 
1.39 (0.98-
1.98) 
 
4 
0.0
% 0.806 
1.32 (0.83-
2.07) 
HPV 82 
2 
0.0% 
0.99
8 
2.00 (0.50-
7.95) 
 
4 
65.1
% 0.035 - 
20-24 year old females          
HPV types included in nonavalent 
vaccine 
 
   
 
    
HPV 31 
3 
57.8
% 
0.09
4 - 
 
5 
0.0
% 0.889 
0.95 (0.81-
1.10) 
HPV 33 
3 
55.0
% 
0.10
8 - 
 
5 
48.1
% 0.103 - 
HPV 45 
3 
74.2
% 
0.02
1 - 
 
5 
56.9
% 0.055 - 
HPV 52 
3 
65.6
% 
0.05
5 
1.26 (0.87, 
1.83) 
 
5 
0.0
% 0.53 
1.28 (1.12-
1.46) 
HPV 58 
3 
0.0% 
0.49
9 
1.17 (0.94-
1.46) 
 
5 
0.0
% 0.684 
1.12 (0.93-
1.34) 
Other high-risk HPV types          
HPV 35 
3 
0.0% 
0.96
8 
1.22 (0.79-
1.87) 
 
5 
43.1
% 0.134 - 
HPV 39 
3 
44.8
% 
0.16
3 
1.32 (0.93, 
1.88) 
 
5 
0.0
% 0.743 
1.09 (0.93-
1.28) 
HPV 51 
3 
0.0% 0.57 
1.37 (1.16-
1.62) 
 
5 
47.0
% 0.11 
1.19 (0.88, 
1.61) 
HPV 56 
3 
75.4
% 
0.01
7 
1.45 (0.82, 
2.59) 
 
5 
87.5
% 
<0.00
1 - 
HPV 59 
3 
86.1
% 
0.00
1 - 
 
5 
0.0
% 0.604 
1.13 (0.94-
1.37) 
39 
 
HPV 68 
3 
67.4
% 
0.04
6 - 
 
5 
0.0
% 0.842 
0.99 (0.72-
1.37) 
Other possibly high-risk HPV types          
HPV 26 
3 
69.0
% 0.04 - 
 
3 
21.1
% 0.282 
1.35 (0.28-
6.47) 
HPV 53 
3 
0.3% 
0.36
7 
1.23 (1.05-
1.45) 
 
3 
16.9
% 0.3 
0.90 (0.64-
1.25) 
HPV 70 
3 
0.0% 
0.38
2 
1.11 (0.81-
1.51) 
 
3 
0.0
% 0.811 
2.47 (1.24-
4.94) 
HPV 73 
3 
43.8
% 
0.16
9 - 
 
3 
76.3
% 0.015 - 
HPV 82 
3 
73.7
% 
0.02
2 - 
  
3 
0.0
% 0.989 
0.94 (0.39-
2.26) 
* Summary prevalence ratio only calculated if data were not shown to be heterogeneous     
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Table S2: Prevalence ratio for non-vaccine high-risk HPV types stratified by age-group and potential bias 
  Relatively low potential bias1   Relatively high potential bias2 
Age-group / HPV type 
Numb
er of 
studies 
Heterogeneity Prevalence 
ratio3 
(95% CI) 
 Numb
er of 
studies 
Heterogeneity Prevalence 
ratio3 
(95% CI) I
2 
p-
value 
 I2 
p-
value 
≤19 year old females          
Nonavalent HPV types           
HPV 31 
5 
31.2
% 0.213 - 
 
3 0.0% 0.447 
0.73 (0.58-
0.93) 
HPV 33 
5 
0.0% 0.526 
0.79 (0.30-
2.06) 
 
3 
34.4
% 0.218 - 
HPV 45 
5 
21.5
% 0.278 
0.84 (0.49-
1.44) 
 
3 0.6% 0.366 
0.99 (0.76-
1.31) 
HPV 52 
5 
0.0% 0.681 
1.09 (0.77-
1.56) 
 
3 
61.9
% 0.072 - 
HPV 58 
5 
0.0% 0.672 
0.87 (0.58-
1.30) 
 
3 0.0% 0.505 
1.08 (0.82-
1.42) 
Other high-risk HPV types          
HPV 35 
5 
0.0% 0.424 
0.85 (0.46-
1.58) 
 
3 
60.6
% 0.079 - 
HPV 39 
5 
0.0% 0.907 
1.21 (0.83-
1.78) 
 
3 0.0% 0.846 
1.30 (1.04-
1.61) 
HPV 51 
5 
45.3
% 0.120 - 
 
3 0.0% 0.433 
1.28 (1.09-
1.50) 
HPV 56 
5 
69.3
% 0.011 - 
 
3 
79.9
% 0.007 - 
HPV 59 
5 
0.0% 0.465 
1.29 (0.94-
1.76) 
 
3 
85.9
% 0.001 - 
HPV 68 
5 
12.6
% 0.333 
1.21 (0.76-
1.93) 
 
3 0.0% 0.948 
1.33 (0.75-
2.36) 
Other possibly high-risk HPV 
types 
 
   
 
    
HPV 26 
5 
3.3% 0.388 
1.27 (0.45-
3.58) 
 
1 - - 
1.93 (0.82, 
4.59) 
HPV 53 
5 
0.0% 0.514 
1.32 (0.92-
1.90) 
 
1 - - 
2.19 (1.18, 
4.04) 
HPV 70 
5 
0.0% 0.831 
0.90 (0.45-
1.76) 
 
1 - - 
4.02 (1.31, 
12.32) 
HPV 73 
5 
0.0% 0.909 
1.33 (0.87-
2.05) 
 
1 - - 
1.39 (0.96, 
2.00) 
HPV 82 
5 
55.0
% 0.064 - 
 
1 - - 
2.00 (0.42, 
9.44) 
20-24 year old females          
Nonavalent HPV types           
HPV 31 
5 
27.7
% 0.237 - 
 
3 0.0% 0.670 
0.95 (0.81-
1.11) 
HPV 33 
5 
0.0% 0.599 
0.64 (0.52-
0.78) 
 
3 0.0% 0.424 
1.03 (0.83-
1.27) 
HPV 45 
5 
78.5
% 0.001 - 
 
3 0.0% 0.948 
0.90 (0.74-
1.10) 
HPV 52 
5 
0.0% 0.905 
1.06 (0.91-
1.22) 
 
3 
11.8
% 0.322 
1.37 (1.20-
1.56) 
HPV 58 
5 
0.0% 0.859 
1.04 (0.85-
1.28) 
 
3 0.0% 0.600 
1.23 (1.02-
1.50) 
Other high-risk HPV types          
HPV 35 
5 
0.0% 0.754 
1.42 (0.97-
2.08) 
 
3 
10.7
% 0.326 
0.90 (0.67-
1.21) 
HPV 39 
5 
8.3% 0.359 
1.12 (0.94-
1.34) 
 
3 0.0% 0.415 
1.14 (0.97-
1.34) 
HPV 51 
5 
32.5
% 0.205 - 
 
3 
46.9
% 0.152 - 
HPV 56 
5 
0.0% 0.914 
1.03 (0.89-
1.21) 
 
3 
94.5
% 0.000 - 
HPV 59 
5 
0.0% 0.443 
1.08 (0.91-
1.28) 
 
3 
86.4
% 0.001 - 
HPV 68 
5 
0.0% 0.692 
1.04 (0.72-
1.49) 
 
3 
72.5
% 0.026 - 
Other possibly high-risk HPV 
types 
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HPV 26 
5 
54.8
% 0.065 - 
 
1 - - 
1.14 (0.37, 
3.50) 
HPV 53 
5 
36.3
% 0.179 - 
 
1 - - 
1.52 (0.86, 
2.69) 
HPV 70 
5 
34.5
% 0.191 - 
 
1 - - 
1.64 (0.79, 
3.37) 
HPV 73 
5 
56.0
% 0.059 - 
 
1 - - 
1.92 (1.04, 
3.53) 
HPV 82 
5 
0.0% 0.984 
0.75 (0.60-
0.94) 
  
1 - - 
0.22 (0.10, 
0.51) 
1 Average-low potential bias includes studies; Cameron et al, Cummings et al, Kahn et al, Markowitz et al, Sonnenberg et al 
and Tabrizi et al 
            2 Average-high potential bias includes studies; Chow et al, Mesher et al and Söderlund-Strand et al 
3 Summary prevalence ratio only calculated if data were not shown to be heterogeneous     
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Table S3: Prevalence ratio for non-vaccine high-risk HPV types stratified by age-group and vaccination coverage 
  Low vaccination coverage (<50%)   High vaccination coverage (≥50%) 
Age-group / HPV type 
Numb
er of 
studies 
Heterogeneity Prevalence 
ratio1 
(95% CI) 
 Numb
er of 
studies 
Heterogeneity Prevalence 
ratio1 
(95% CI) I
2 
p-
value 
 I2 
p-
value 
≤19 year old females          
Nonavalent HPV types           
HPV 31 
0 
- 
 
8 6.4% 0.381 
0.73 (0.58-
0.91) 
HPV 33 
0 
- 
 
8 0.0% 0.471 
1.04 (0.78-
1.38) 
HPV 45 
0 
- 
 
8 5.5% 0.387 
0.96 (0.75-
1.23) 
HPV 52 
0 
- 
 
8 
24.0
% 0.238 
1.34 (1.13-
1.59) 
HPV 58 
0 
- 
 
8 0.0% 0.727 
1.01 (0.80-
1.26) 
Other high-risk HPV types          
HPV 35 
0 
- 
 
8 
25.1
% 0.229 - 
HPV 39 
0 
- 
 
8 0.0% 0.984 
1.27 (1.05-
1.54) 
HPV 51 
0 
- 
 
8 
43.6
% 0.088 - 
HPV 56 
0 
- 
 
8 
74.3
% 
<0.00
1 - 
HPV 59 
0 
- 
 
8 
66.8
% 0.004 - 
HPV 68 
0 
- 
 
8 0.0% 0.690 
1.26 (0.88-
1.81) 
Other possibly high-risk HPV 
types 
 
        
HPV 26 
0 
- 
 
6 0.0% 0.478 
1.63 (0.84-
3.16) 
HPV 53 
0 
- 
 
6 3.6% 0.394 
1.51 (1.10-
2.06) 
HPV 70 
0 
- 
 
6 
23.6
% 0.257 
1.34 (0.75-
2.39) 
HPV 73 
0 
- 
 
6 0.0% 0.961 
1.36 (1.03-
1.80) 
HPV 82 
0 
- 
 
6 
49.0
% 0.081 - 
20-24 year old females          
Nonavalent HPV types           
HPV 31 
5 
0.0% 0.838 
0.96 (0.83-
1.12) 
 
3 
25.5
% 0.261 - 
HPV 33 
5 
36.3
% 0.179 - 
 
3 0.0% 0.618 
0.65 (0.53-
0.81) 
HPV 45 
5 
55.9
% 0.06 - 
 
3 
62.7
% 0.068 - 
HPV 52 
5 
26.1
% 0.248 - 
 
3 0.0% 0.513 
1.10 (0.94-
1.27) 
HPV 58 
5 
0.0% 0.689 
1.21 (1.01-
1.45) 
 
3 0.0% 0.807 
1.04 (0.83-
1.30) 
Other high-risk HPV types          
HPV 35 
5 
30.4
% 0.219 - 
 
3 0.0% 0.590 
1.29 (0.80-
2.07) 
HPV 39 
5 
5.3% 0.377 
1.17 (1.00-
1.37) 
 
3 0.0% 0.482 
1.08 (0.89-
1.30) 
HPV 51 
5 
56.7
% 0.056 - 
 
3 
37.8
% 0.201 - 
HPV 56 
5 
30.5
% 0.218 - 
 
3 
91.7
% 
<0.00
1 - 
HPV 59 
5 
73.5
% 0.004 - 
 
3 0.0% 0.673 
1.15 (0.96-
1.37) 
HPV 68 
5 
61.7
% 0.034 - 
 
3 0.0% 0.810 
1.20 (0.78-
1.85) 
Other possibly high-risk HPV 
types 
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HPV 26 
4 
53.8
% 0.09 - 
 
2 0.0% 0.862 
1.76 (1.00-
3.12) 
HPV 53 
4 
0.0% 0.522 
1.31 (0.95-
1.81) 
 
2 
76.6
% 0.039 - 
HPV 70 
4 
11.8
% 0.334 
1.72 (1.06-
2.79) 
 
2 0.0% 0.335 
1.08 (0.76-
1.53) 
HPV 73 
4 
52.5
% 0.097 - 
 
2 0.0% 0.503 
1.02 (0.82-
1.26) 
HPV 82 
4 
33.7
% 0.21 - 
 
2 0.0% 0.675 
0.75 (0.59-
0.94) 
1 Summary prevalence ratio only calculated if data were not shown to be heterogeneous     
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